(MedPage Today) — Treatment with a once-daily FGFR1-3 tyrosine kinase inhibitor led to significant increases in growth among children with achondroplasia, the phase III PROPEL 3 study showed.
The least-squares mean change from baseline in the…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
